CEPI is funding 4 analysis tasks to evaluate whether or not vaccines licensed in opposition to Zaire ebolavirus, together with Ervebo, might present safety in opposition to Bundibugyo ebolavirus.
New research are underway to evaluate if vaccines licensed in opposition to the Zaire ebolavirus—together with Ervebo—might provide safety in opposition to Bundibugyo ebolavirus, the virus behind the quickly escalating outbreak within the Democratic Republic of the Congo. The research are supported by the worldwide organisation CEPI – the Coalition for Epidemic Preparedness Improvements, which is offering $4.17 million to 4 analysis tasks conducting them.
The Ebola outbreak was declared a Public Well being Emergency of Worldwide Concern by the World Well being Organisation (WHO) in Could 2026. The 4 awardees endeavor the research embrace analysis teams led by UCLA (USA), the Institute of Tropical Drugs (Antwerp), the College of Oxford (UK), and the MRC-College of Glasgow Centre for Virus Analysis (UK).
“There isn’t a licensed vaccine in opposition to Bundibugyo virus. CEPI is funding a number of Bundibugyo vaccine candidates to handle this hole, however even on probably the most compressed timelines these vaccines is not going to be accessible for the earliest section of this outbreak”, mentioned Dr Richard Hatchett, CEPI Chief Government Officer. “Nonetheless, vaccines do exist for the associated Zaire ebolavirus, together with Ervebo. Given the latest announcement that Ervebo shall be deployed for emergency use in opposition to Bundibugyo virus, these CEPI-backed research shall be all of the extra necessary to tell on how we will make the most effective use of the present vaccine,” he added.
Explaining how it could work, CEPI mentioned analysis groups will analyse saved blood samples from people vaccinated with licensed/beforehand licensed vaccines in opposition to Zaire ebolavirus both in earlier vaccination campaigns and/or scientific trials. They intention to characterise vaccine-induced immune responses and assess cross-reactivity of antibody responses in opposition to Bundibugyo ebolavirus.
The important knowledge that these serology research will present will assist set up and standardise checks for antibodies in opposition to Bundibugyo virus and use longitudinal samples to outline the dynamics and sturdiness of those responses, it defined. Knowledge from these research will even support interpretation of immune responses in scientific trials, assist assess whether or not Bundibugyo-specific antibodies are related to safety, and inform future vaccination methods and analysis of Bundibugyo-specific and broadly protecting filovirus vaccines, CEPI mentioned.
Printed on August 20, 2026
